PTPRB and neoplasm: Given the reduced ANGPTL1/TEK signaling in MDA-MB-231 VMT and clinical TNBC, which correlates with disrupted vasculature, our objective was to investigate the potential benefits of increasing TEK signaling in the tumor EC by blocking VE-PTP with razuprotafib.